We request you to take a moment to read and support Bill S- 201: The Genetic Non-Discrmination Act, which is currently under consideration by the Parliament of Canada. The President of CCMG, Dr. Gail Graham says “If passed, Bill S-201 will make it illegal to require an individual to undergo a genetic test as a condition of providing goods or services, including insurance, to that individual. Similarly, insurers will not be allowed to deny insurance to an individual on the grounds that they have refused to undergo a genetic test. Canada is the only G7 country without this type of legislation. All of us in this field are acutely aware of how genetic testing is transforming health care. Genome-wide technologies are cheaper and more accessible than ever. Whole exome sequencing is now being used for clinical care and the movement toward “personalized medicine” is well underway. Those of us on the front line of patient care understand how fear of genetic discrimination can influence genetic test decisions. Fear of repercussions should not prevent our society from realizing the potential of genomics. I personally believe that Canadians deserve this type of protection. If you support Bill S-201, please take a moment to write to or email your Member of Parliament (M.P.) to let him or her know. You can quickly find the address and email of your member of Parliament“
ASHG has recently issued a statement of support for S-201, and is working with Canadian organizations to move the bill forward.
Quebec’s Network of Applied Medical Genetics (RMGA) has also released a position statement, in support of Bill S-201.
Read the full text of Bill S-201
Stand Up To Cancer Canada’s (SU2C)- New Cancer Stem Cell Dream Team
Congratulations to Dr. Nada Jabado on being named Principal Investigator of the SU2C Canada Cancer Stem Cell Dream Team. “The Dream Team will bring new insights to brain cancer research, which has been an underfunded area.” “In their search for new treatment approaches in two of the most devastating cancers, both in brain, in adults and children – glioblastomas and infant ependymomas – the Dream Team will focus on a specific type of cell, called brain tumor stem cells (BTSCs).”
Dr. Nada Jabado along with Research Teams from across Canada will receive $11.7 Million in funding from SU2C, Genome Canada, Canadian Institutes of Health Research, Cancer Stem Cell Consortium and Ontario Institute for Cancer Research.
Dr. Nada Jabado, Senior Scientist at RI-MUHC, Professor at the Department of Human Genetics, Faculty of Medicine, McGill University research focuses on brain tumors, the leading cause of cancer-related mortality and morbidity in the pediatric years. Using Next Generation Sequencing, her research team was among the first to use and achieve a breakthrough in cancer research. Published in the journals Nature, and Cancer Cell her work identified two genetic mutations involved in up to 40% of pediatric glioblastomas, a fatal cancer of the brain.Read More Posts From This Section »
- Vanier Canada Graduate Scholarship Program. Departmental submission deadline: September 12, 2016
- PostDoc Fellow: In Computational Genomic Laboratory (CGL) at Queen’s University, Kingston, ON
- PostDoc Fellow: In Zellweger Spetrum Disorders at NIH, Rockville, MD, USA